Navigation Links
Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
Date:11/12/2013

s of the Light Study excluding a prespecified level of risk of MACE; the potential for, and timing of, resubmission of a NDA for Contrave based on interim results of the Light Study; the possibility of resubmitting the Contrave NDA with the independent DMC report on the interim analysis and without the clinical study report for the interim analysis; the safety and effectiveness of Contrave; the potential for, and timing of, the accrual and adjudication of MACE in the Light Study; the probability of overall success of the Light Study; the potential for past Contrave clinical trials to predict the outcome of future Contrave clinical trials; the potential for the FDA to continue to honor the Special Protocol Assessment, or SPA; the potential to enter into a collaborative partnership for commercialization of Contrave outside of North America; the potential for Takeda to commercially launch Contrave in North America; the potential to enter into a collaborative partnership to fund Phase 3 development and, if approved, commercialization of Empatic™; the potential for the FDA to approve an NDA for Empatic without requiring data from a cardiovascular outcomes trial in addition to the data obtained from the Light Study; and the use of pharmacotherapy to treat obesity. The inclusion of forward‐looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the complete study report for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fai
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
2. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
3. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
4. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
7. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
10. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
11. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... DIEGO , Oct. 20, 2014 ... industry leader in bioactive lipid-targeted therapeutics, received official notification ... has been granted another key patent supporting its ... newly issued patent, European patent No. 2087002, claims ... substance in Lpath,s two lead compounds, iSONEP and ...
(Date:10/20/2014)... 2014 Norgine B.V. today announced ... volume bowel preparation, NER1006, presented at the 79 th ... Gastroenterology (ACG), Philadelphia, PA , has ... and co-primary endpoint of cleansing success. The study demonstrated ... ® in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... Oct. 20, 2014 CTI BioPharma Corp. (CTI) ... report its third quarter 2014 financial results on Wednesday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at ... event can be obtained as follows: Wednesday, ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... Nov. 16 Announced on November 06, 2009 by Mr. ... Inc., and the Board of MEGGLE Group of Wasserburg, Germany, ... Mr. Christian Sedlatschek, CFO, the companies are entering a long-term ... States. , DAVISCO Foods is an international cheese and food ...
... , ACPCN Joins Congressional Leaders to Introduce Legislation ... Association of Community Pharmacists Congressional Network (ACPCN) will join ... Real Medication Access Cost Savings Act." The bill ... dependence on pharmacy benefit management (PBM) companies for medications. ...
Cached Medicine Technology:DAVISCO Foods International, Inc. and MEGGLE Group Announce a Joint Venture for the Production of Pharmaceutical Lactose. 2Pharmacists Work with Congress to Address PBM Abuses 2
(Date:10/20/2014)... (PRWEB) October 20, 2014 It’s hard to ... many orphans and vulnerable children around the world, it’s a ... some people, many children are forced to walk barefoot on ... their families or play with their friends. , Buckner ... with Air1 Radio in October to encourage support ...
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... 20, 2014 Recently, BambooIndustry.com, one of ... its new range of bamboo deckings . Moreover, ... natural items; they are now available at deeply discounted ... it is hard to overstate the significance of online ... to online services. The company’s workers are striving to ...
(Date:10/19/2014)... working in the garment industry for decades, LunaDress’ dress specialists ... one of the company’s top designers, many ladies like prom ... add beauty to them. Chiffon floor length outfits are also ... selection of 2014 long prom dresses. , As a ... in over 20 popular designs. The company intends to meet ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and ... evening dresses . All the company’s old and ... discount is up to 66 percent off. , ... fashion field. Its dress specialists are striving to make ... of the world. All the company’s items are unique, ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... At NYU Langone Medical Center the focus on quality, ... stroke initiatives but measureable, quantifiable and concrete. Patients ... to world-class care and operational transparency in the Department ... Report," which is now available online as well as ...
... the strongest known risk factors for spontaneous or unexpected preterm ... of pregnancy, most often without a known cause is ... would like to avoid this scenario in their second pregnancy, ... the best strategy. A new study reported at the Society ...
... PHILADELPHIACurcumin, an active component of the Indian curry spice ... prostate cancer patients on androgen deprivation therapy (ADT), a ... suggests. Reporting in a recent issue ... , a Professor of Cancer Biology, Urology and Radiation ...
... HealthDay Reporter , THURSDAY, Feb. 9 (HealthDay News) ... marijuana nearly doubles a driver,s risk of having an accident, ... especially high for fatal crashes, and the risk is only ... Canadian researchers say. "On the whole, alcohol increases the ...
... New research presented at the 2012 Annual Meeting of ... more than 4.5 million Americans are living with a ... surgeries has more than doubled over the past decade, ... to be the primary reason for TKR., Investigators used ...
... In a study to be presented today at ... Meeting , in Dallas, Texas, researchers will report that ... the lateral ventricles of neonatal rats with birth-related brain ... survive and migrate in the recipient,s brain. The ...
Cached Medicine News:Health News:Orthopaedic surgery report provides transparency on patient safety, quality initiatives 2Health News:To avoid early labor and delivery, weight and diet changes not the answer 2Health News:Curry spice component may help slow prostate tumor growth 2Health News:Pot Use Could Double Risk of Car Crash, Research Shows 2Health News:Pot Use Could Double Risk of Car Crash, Research Shows 3Health News:Pot Use Could Double Risk of Car Crash, Research Shows 4Health News:4.5 million Americans living with total knee replacement 2Health News:Neurologic improvement detected in rats receiving stem cell transplant 2
Posterior Capsule Polisher, 21 g. Roughened tip, top port. Overall length 23 mm. 5/box....
Irrigating Capsulorhexis Cystotome. Formed angled tip, 27 g. Overall length 16 mm. 5/box....
Irrigating Cystotome, formed, 27 g., short 8 mm curved tip. Overall length 14 mm. 5/box....
Peribulbar Needle, 25 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Medicine Products: